top of page

Leadership and Board of Directors



Jeffrey L. Goldberg, MD, PhD

Co-founder and Director, Board of Managers 

Dr. Jeffrey Goldberg is Professor and Chair of Ophthalmology and Director of the Byers Eye Institute at Stanford University. His focus is on regenerative medicine in eye and vision research,  and on developing novel molecular, stem cell, and nanotherapeutics approaches for eye repair. Jeff completed his clinical training in ophthalmology and glaucoma at the Bascom Palmer Eye Institute. He received his BS magna cum laude from Yale, and his MD and PhD from Stanford.


Roger A. Goldberg, MD, MBA

Co-founder and Chief Medical Advisor

Dr. Roger Goldberg is a vitreoretinal surgeon with expertise in clinical trial design and implementation. He did his clinical training in ophthalmology at the Bascom Palmer Eye Institute and vitreoretinal fellowship at Tufts University. Previously, Roger worked for McKinsey & Co. in healthcare consulting. He received his BA, MD, and MBA from Yale.


Noelia J. Kunzevitzky, PhD

Chief Operating Officer

Dr. Kunzevitzky focuses on innovation and regenerative medicine. An executive with over 20 years of experience in ophthalmology,  she leads teams in pre-clinical development, cell manufacturing, regulatory project management, and clinical trials. Noelia obtained her BS at Universidad Nacional de Cordoba in Argentina and completed her PhD in cell biology and postdoctoral training in bioinformatics at the University of Miami.

Cyril website_edited_edited.jpg

Cyril Allouche, MBA

Chief Financial Advisor

Mr. Allouche brings over 25 years of experience in finance leadership in both public and pre-IPO companies, including biopharmaceutical, medical devices, and diagnostics. He most recently served as CFO at Avellino Lab, LensGen, Dermavant Sciences and held finance leadership roles at Revance Therapeutics and CareDx. He also spent over a decade at PricewaterhouseCoopers in Audit and Transaction services. Cyril is a California Certified Public Accountant and holds a Master of Accountancy from University of Georgia and a Master of Business Administration from University of Paris-East.


James V. Mazzo

Board of Directors

James V. (Jim) Mazzo is the Executive Chair of Neurotech, a private clinical-stage biotech company developing transformative therapies for chronic eye diseases. One of the ophthalmic industry's most respected business leaders with more than 40 years of proven experience in the medical device space, Mr. Mazzo is internationally renowned for building and running world-class organizations. He has held several leadership positions, including CEO of Allergan's North American and European eye care organizations; chairman, president and CEO of Advanced Medical Optics (AMO);  EVP of Abbott's global ophthalmology business; executive chair and CEO of AcuFocus; and global president of ophthalmic devices for Carl Zeiss Meditec.

JD4_edited copy_edited_edited.jpg

James W. Donaghy, MBA

Board of Directors

Mr. Donaghy has over thirty years experience in private equity investing. He serves as the President and is on the Board of Holding Capital Groups' principal investment entities. He also serves (or has served) on the Boards of portfolio companies in precision injection molding, building materials, men's apparel, wire and cable, concrete products, and metal and rubber manufacturing industries amongst others. Mr. Donaghy holds a BS in Business Administration from the University of Nebraska and an MBA from Pace University.

Cornea Advisory Board

Retina Advisory Board

bottom of page